Nitric Oxide in Health and Disease

Therapeutic Applications in Cancer and Inflammatory Disorders
Erscheinungsjahr 2023
ISBN: 978-0-443-13342-8
Verlag: Elsevier Science Publishing Co Inc

Buch, Englisch, 364 Seiten, Format (B × H): 233 mm x 191 mm, Gewicht: 738 g

Approx.326 pages

Autoren/Hrsg.

Bonavida, Benjamin

Muntané, Jordi

Muntane, Jordi

Morbidelli, Lucia

Fachgebiete

• Wirtschaftswissenschaften Betriebswirtschaft Unternehmensforschung
• Mathematik | Informatik EDV | Informatik Business Application Unternehmenssoftware

Inhaltsverzeichnis

Section 1: General properties of NO/metabolites in human diseasesSection 2: Development of novel NO donors/inhibitors and NO complexes: properties, cell signaling, synergy Section 3: Pharmacokinetics of NO donors/inhibitors in animal models and toxicities Section 4: Red-Ox signaling and modification of proteins. Characterization of their modified functions Section 5: Therapeutic applications of NO donors/inhibitors in non-cancer related human diseases Section 6: Therapeutic applications of NO donors/inhibitors in various cancersConcluding remarks and future perspectives

Über Autor(innen)

Muntané, Jordi
Dr. Muntané's scientific career has been all devoted to the study of the relevance of oxidative and nitrosative stress in cell proliferation and death in different experimental models and clinical settings such as acute hepatocellular injury and hepatocarcinoma. The relevance of the temporal, dose and compartmentalization of nitric oxide (NO) release has been related to cytotoxicity, as well as the cytoprotective properties of classical antioxidants, prostanoids and alpha-tocopherol in different experimental models of liver injury. The anti-tumoral properties of NO has also been demonstrated using NO-donors and nitric oxide synthase type III (NOS3) overexpression in in vivo and in vitro models. The involvement of NO in the antitumoral properties of the molecular recommended therapies for patients with advanced hepatocarcinoma, such as the tyrosine kinase inhibitor Sorafenib, has also been studied comprehensively by Dr. Muntané's lab.